Abstract
With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells. For the past few years, significant progress has been made in various BCMA-targeted immunotherapies for treating patients with RRMM, including anti-BCMA mAbs, antibody-drug conjugates, bispecific T-cell engagers, and BCMA-targeted adoptive cell therapy like chimeric antigen receptor (CAR)-T cell. The 63rd annual meeting of the American Society of Hematology updated some information about the application of BCMA in MM. This review summarizes part of the related points presented at this conference.
Highlights
In recent years, the strategies for treating multiple myeloma (MM) have advanced across the board [1]
Multiple kinds of B-cell maturation antigen (BCMA)-targeted immunotherapies, including antibody-drug conjugates (ADCs), BsAbs, and adoptive cell therapies have presented gratifying results of their primeval clinical trials, there are still many hurdles that need to be overcome before they go into real-world service to benefit more suffering patients with refractory multiple myeloma (RRMM)
Anti-BCMA chimeric antigen receptor (CAR)-T-cell therapy with better performance requires more complex preparation conditions and more expensive treatment costs, which are difficult for ordinary families to afford [130]
Summary
The strategies for treating multiple myeloma (MM) have advanced across the board [1]. From the finding of targeted monoclonal antibodies (mAbs), which have a favorable curative effect in MM [3, 4], the treatment for MM has shifted to focus on multiple immunotherapies, and their most salient point was undoubtedly targeted immunotherapy. B-cell maturation antigen (BCMA/CD269), which belongs to TNF receptor superfamily member 17 [5], is highly selectively expressed on the surface of MM cells, as the ideal target of majority targeted agents studied currently for the patients with MM [6], such as anti-BCMA mAbs, antibody-drug conjugates (ADCs), bispecific T-cell engagers (BiTEs), and BCMA-targeted adoptive cell therapy like chimeric antigen receptor (CAR)-T cell (Figure 1). This review aims to summarize some of the main points in this meeting about the application of BCMA in MM, with a special focus on clinical achievements
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
